Zoetis (ZTS), the animal health company, is anticipated to surpass its upcoming earnings estimates, extending a consistent record of outperforming consensus expectations. The company has exceeded EPS estimates by an average of 7.18% over the last two quarters, including an 8.64% surprise in its most recent report ($1.76 vs. $1.62). This positive outlook is further supported by a +0.41% Zacks Earnings ESP and a Zacks Rank #3 (Hold), a combination historically indicating a high probability of an earnings beat.
Zoetis (ZTS), an animal health company within the Zacks Medical - Drugs industry, is positioned for another earnings beat, extending its consistent outperformance. The company has surpassed EPS estimates by an average of 7.18% over the last two quarters. Specifically, ZTS reported $1.76 per share against a Zacks Consensus Estimate of $1.62 in its last quarter, marking an 8.64% positive surprise. This consistent trend suggests robust operational execution and effective management of analyst expectations. This positive outlook is reinforced by key predictive metrics. Zoetis currently holds a positive Zacks Earnings ESP of +0.41% and a Zacks Rank #3 (Hold). This combination historically indicates a high probability, approximately 70%, of an earnings beat, suggesting analysts have recently become more bullish on the company's near-term prospects. The upward trend in estimates, partly driven by past surprises, suggests a strong fundamental position within the animal health sector. The next earnings report for Zoetis is anticipated on November 4, 2025, which will be a key event to confirm these positive indicators.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
